EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496

被引：0
|
作者：
Evens, A. M. [1 ]
Hong, F. [2 ]
Gordon, L. I. [3 ]
Fisher, R. I. [4 ]
Bartlett, N. [5 ]
Connors, J. M. [6 ]
Wagner, H. [7 ]
Gospodarowicz, M. [8 ]
Cheson, B. D. [9 ]
Advani, R. [10 ]
Kahl, B. S. [11 ]
Hoppe, R. T. [10 ]
Horning, S. J. [12 ]
机构：
[1] Univ Massachusetts, Worcester, MA 01605 USA
[2] Harvard Univ, ECOG Stat Ctr, Boston, MA 02115 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14627 USA
[5] Washington Univ, St Louis, MO USA
[6] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada
[7] Penn State Canc Inst, Hershey, PA USA
[8] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[9] Georgetown Univ Hosp, Washington, DC 20007 USA
[10] Stanford Univ, Stanford, CA 94305 USA
[11] Univ Wisconsin, Madison, WI 53706 USA
[12] Genentech Inc, Clin Dev, San Francisco, CA 94080 USA
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 118
页数：2
相关论文
共 35 条
  • [31] Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated followed by 4 Cycles of BEACOPP Baseline with or without Radiotherapy in Patients in Advanced-stage Hodgkin Lymphoma (HL): Final Analysis of the Randomized HD12 Trial of the German Hodgkin Study Group (GHSG)
    Eich, H.
    Engert, A.
    Haverkamp, H.
    Staar, S.
    Kriz, J.
    Engenhart-Cabillic, R.
    Lukas, P.
    Willich, N.
    Diehl, V.
    Mueller, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S3 - S4
  • [32] Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi
    Merli, Francesco
    Luminari, Stefano
    Mammi, Caterina
    Cascavilla, Nicola
    Bari, Alessia
    Stelitano, Caterina
    Scalone, Renato
    Baldini, Luca
    Angrilli, Francesco
    Polimeno, Giuseppe
    Gobbi, Paolo G.
    Cervetti, Giulia
    Ilariucci, Fiorella
    Ruffini, Alessia
    Marcheselli, Luigi
    Federico, Massimo
    BLOOD, 2014, 124 (21)
  • [33] 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
    Morschhauser, Franck
    Radford, John
    Van Hoof, Achiel
    Botto, Barbara
    Rohatiner, Ama Z. S.
    Salles, Gilles
    Soubeyran, Pierre
    Tilly, Herve
    Bischof-Delaloye, Angelika
    van Putten, Wim L. J.
    Kylstra, Jelle W.
    Hagenbeek, Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 1977 - +
  • [34] Quality of life (QOL) analysis from the phase 3 randomized first-line indolent trial (FIT) in patients with advanced-stage follicular lymphoma receiving consolidation of first remission with 90Y-ibritumomab tiuxetan (Zevalin)
    Vitolo, U.
    Valderrama, A.
    d'Amore, F.
    Diaz, M. Gonzalez
    O'Rourke, N.
    Petrini, M.
    Sebban, C.
    Zinzani, P. L.
    Hagenbeek, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 207 - 208
  • [35] 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients
    Hagenbeek, Anton
    Radford, John
    Van Hoof, Achiel
    Vitolo, Umberto
    Rohatiner, Ama Z. S.
    Salles, Gilles
    Soubeyran, Pierre
    Tilly, Herve
    Delaloye, Angelika Bischof
    van Putten, Wim L. J.
    Morschhauser, Franck
    BLOOD, 2010, 116 (21) : 261 - 262
1234